Navigation Links
Hyperthyroidism linked to increased risk of hospitalization for heart and blood-vessel disease
Date:6/23/2012

An overactive thyroid gland, or hyperthyroidism, may increase the risk of hospitalization for heart and blood-vessel disease even after surgery to remove the gland, according to a new study. The results will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.

"Overactive thyroid gland has long-lasting effects on the patient's heart and vessels," said study principal investigator Saara Metso, M.D., Ph.D. assistant chief of endocrinology in the Department of Internal Medicine, Division of Endocrinology, at Tampere University Hospital in Tampere, Finland. "Therefore, it is important to monitor the patient's heartbeat and blood pressure even years after the overactive thyroid gland has been cured."

The thyroid gland, located in the front of the neck, produces thyroid hormone, which helps regulate the process of turning food into energy. When the gland is overactive and produces excessive hormone, many bodily processes speed up. Symptoms include unexplained weight loss, rapid heart rate, increased appetite, profuse sweating, and feelings of anxiety.

Diagnosis of an overactive thyroid gland usually involves a simple blood test, and effective treatments are available. These include radioactive iodine, which destroys part of the thyroid gland; antithyroid medication to reduce thyroid-hormone synthesis; and surgery, or a thyroidectomy, to remove it.

Recently, however, questions were raised about the long-term health effects of treatment after some studies found that patients who had received radioactive iodine treatment or antithyroid medication had an increased risk of hospitalization for heart and blood-vessel disease. This risk persisted long after therapy ended, but it was unclear whether it was associated with the treatment itself or the prior overactive thyroid.

In findings implicating the disease rather than the treatment, the current study showed that patients who had undergone surgical thyroid removal also were at greater risk of being hospitalized for heart and blood-vessel disease. Overall, their risk was 17 percent greater compared to those without a history of overactive thyroid, and the increased risk persisted for as long as two decades after surgery.

"Although overactive thyroid gland is usually easy to diagnose and treat, it may be injurious to the patient's heart and vessels," Metso said. "It is probably the disease rather than the treatment that affects the patient's heart and vessels permanently."

Participants included 4,334 patients diagnosed with overactive thyroid who underwent thyroidectomy in Finland between 1986 and 2007, and 12,991 age- and gender-matched controls. They were 86 percent female, their average age was 46 years, and all were white. Average follow-up was 10.5 years.

Investigators obtained hospitalization information from Finland's national Hospital Discharge Registry for the study. They received funding from Research Funding of the Pirkanmaa Hospital District, Finland.

Hyperthyroidism affects approximately 1 percent of the U.S. population. The most common cause is an autoimmune disorder called Grave's disease.


'/>"/>

Contact: Aaron Lohr
alohr@endo-society.org
240-482-1380
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Antibiotics Linked to Retinal Detachment Risk
2. Pesticides May Be Linked to Slightly Smaller Babies, Shorter Pregnancies
3. Pharmacy Robots Linked to Bacterial Contamination of Drugs
4. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
5. Dental X-Rays May Be Linked to Benign Brain Tumors
6. In Mice, Drug Reverses Symptoms of Condition Linked to Autism
7. Huntingtons Disease Linked to Reduced Cancer Risk in Study
8. Study finds significant skull differences between closely linked groups
9. Researchers Map Brain Regions Linked to Intelligence
10. Swallowing exercises linked with short-term improvement among patients with head and neck cancer
11. Anxiety Linked to Smarts in Brain Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest ... chronic problems, I focus on preventative care with all my patients to alleviate possible future ... always feel free to contact my office and my trained staff will assist you in ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency ... Series, Outliers in Writing, set to publish in summer 2017. , Dr. Bobrow, ... University of Arizona College of Medicine. He also serves as Medical Director for the ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
Breaking Medicine Technology: